{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:10:25Z","timestamp":1787314225026,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":786,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.24875\/ric.23000108","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:02:26Z","timestamp":1688583746000},"page":"169-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Resurgence of Hallucinogen Drugs in Clinical Research"],"prefix":"10.1016","volume":"75","author":[{"given":"Maria T.","family":"Rivera-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia L.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.24875\/RIC.23000108_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.24875\/RIC.23000108_bib2","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1111\/add.15987","article-title":"Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP","volume":"117","author":"Livne","year":"2022","journal-title":"Addiction"},{"key":"10.24875\/RIC.23000108_bib3","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr Biol"},{"key":"10.24875\/RIC.23000108_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415574","article-title":"Arylcyclohexylamine derivatives: pharmacokinetic, pharmacodynamic, clinical and forensic aspects","volume":"23","author":"Pelletier","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.24875\/RIC.23000108_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1192\/bjp.bp.116.194738","article-title":"Psychedelics and the science of self-experience","volume":"210","author":"Nour","year":"2017","journal-title":"Br J Psychiatry"},{"key":"10.24875\/RIC.23000108_bib6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.24875\/RIC.23000108_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26102948","article-title":"The therapeutic potential of psilocybin","volume":"26","author":"Lowe","year":"2021","journal-title":"Molecules"},{"key":"10.24875\/RIC.23000108_bib8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: a review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.24875\/RIC.23000108_bib9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/npp.2017.86","article-title":"Modern clinical research on LSD","volume":"42","author":"Liechti","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.24875\/RIC.23000108_bib10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.115.229765","article-title":"In Vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1","volume":"357","author":"Simmler","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.24875\/RIC.23000108_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/1570159X16666180125095902","article-title":"Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness","volume":"17","author":"Hamill","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.24875\/RIC.23000108_bib12","first-page":"106","article-title":"Toxicological aspects and determination of the main components of ayahuasca: a critical review","volume":"6","author":"Simao","year":"2019","journal-title":"Medicines (Basel)"},{"key":"10.24875\/RIC.23000108_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111618","article-title":"Molecular pathways of the therapeutic effects of ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant","volume":"12","author":"Rossi","year":"2022","journal-title":"Biomolecules"},{"key":"10.24875\/RIC.23000108_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13659-019-0210-5","article-title":"Ayahuasca: uses, phytochemical and biological activities","volume":"9","author":"Estrella-Parra","year":"2019","journal-title":"Nat Prod Bioprospect"},{"key":"10.24875\/RIC.23000108_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am J Psychiatry"},{"key":"10.24875\/RIC.23000108_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/cpt.2821","article-title":"Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants","volume":"113","author":"Holze","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.24875\/RIC.23000108_bib17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr Mol Pharmacol"},{"key":"10.24875\/RIC.23000108_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109294","article-title":"Mescaline: the forgotten psychedelic","volume":"222","author":"Vamvakopoulou","year":"2023","journal-title":"Neuropharmacology"},{"issue":"2 Suppl","key":"10.24875\/RIC.23000108_bib19","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1038\/sj.npp.1395318","article-title":"Serotonin and hallucinogens","volume":"21","author":"Aghajanian","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.24875\/RIC.23000108_bib20","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dta.1333","article-title":"Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model","volume":"4","author":"Canal","year":"2012","journal-title":"Drug Test Anal"},{"key":"10.24875\/RIC.23000108_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1523\/JNEUROSCI.1659-20.2020","article-title":"Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine","volume":"41","author":"De Gregorio","year":"2021","journal-title":"J Neurosci"},{"key":"10.24875\/RIC.23000108_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","article-title":"Neuropharmacology of N,N-dimethyltryptamine","volume":"126","author":"Carbonaro","year":"2016","journal-title":"Brain Res Bull"},{"key":"10.24875\/RIC.23000108_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111953","article-title":"d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology","volume":"17","author":"De Gregorio","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.24875\/RIC.23000108_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911450","article-title":"Esketamine and psilocybin-the comparison of two mind-altering agents in depression treatment: systematic review","volume":"23","author":"Psiuk","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.24875\/RIC.23000108_bib25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.24875\/RIC.23000108_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat Rev Neurosci"},{"key":"10.24875\/RIC.23000108_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.24875\/RIC.23000108_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/15622975.2019.1679391","article-title":"Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex","volume":"21","author":"Woelfer","year":"2020","journal-title":"World J Biol Psychiatry"},{"key":"10.24875\/RIC.23000108_bib29","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fncel.2019.00363","article-title":"Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain","volume":"13","author":"Miranda","year":"2019","journal-title":"Front Cell Neurosci"},{"key":"10.24875\/RIC.23000108_bib30","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. United States: American Psychiatric Association."},{"key":"10.24875\/RIC.23000108_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav Brain Res"},{"key":"10.24875\/RIC.23000108_bib32","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.24875\/RIC.23000108_bib33","first-page":"720","article-title":"Demystifying serotonin syndrome (or serotonin toxicity)","volume":"64","author":"Foong","year":"2018","journal-title":"Can Fam Physician"},{"key":"10.24875\/RIC.23000108_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/0269881119857204","article-title":"Microdosing psychedelics: more questions than answers? An overview and suggestions for future research","volume":"33","author":"Kuypers","year":"2019","journal-title":"J Psychopharmacol"},{"key":"10.24875\/RIC.23000108_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2045125316689030","article-title":"Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies","volume":"7","author":"Dos Santos","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.24875\/RIC.23000108_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/09540261.2020.1854194","article-title":"Ketamine for depression","volume":"33","author":"Jelen","year":"2021","journal-title":"Int Rev Psychiatry"},{"key":"10.24875\/RIC.23000108_bib37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.24875\/RIC.23000108_bib38","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.24875\/RIC.23000108_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.24875\/RIC.23000108_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.24875\/RIC.23000108_bib41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N Engl J Med"},{"key":"10.24875\/RIC.23000108_bib42","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.24875\/RIC.23000108_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-14809-3","article-title":"Associations between classic psychedelics and nicotine dependence in a nationally representative sample","volume":"12","author":"Jones","year":"2022","journal-title":"Sci Rep"},{"key":"10.24875\/RIC.23000108_bib44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.24875\/RIC.23000108_bib45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J Clin Psychopharmacol"}],"container-title":["Revista de Investigaci\u00f3n Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837625001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034837625001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.clinicalandtranslationalinvestigation.com\/frame_esp.php?id=466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:02:03Z","timestamp":1751356923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034837625001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0034837625001457"],"URL":"https:\/\/doi.org\/10.24875\/ric.23000108","relation":{},"ISSN":["0034-8376"],"issn-type":[{"value":"0034-8376","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Resurgence of Hallucinogen Drugs in Clinical Research","name":"articletitle","label":"Article Title"},{"value":"Revista de Investigaci\u00f3n Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.24875\/RIC.23000108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 Revista de Investigaci\u00f3n Cl\u00ednica. Published by Permanyer. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}